Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

Inclusion Criteria: * Men and women, between the ages of 18 and 70 years of age, inclusive, at the time of randomization; * Diagnosis of discoid lupus erythematosus (DLE) with or without SLE; * Intolerance of anti-malarial therapy or ≥ 3 months of anti-malarial therapy with residual disease activity. The total CLASI activity must be ≥ 10; * Stable dose of topical steroids no stronger than medium-potency (Class III or less) for ≥ 2 weeks and/or systemic immunosuppressive therapy at stable dose for ≥ 8 weeks prior to randomization (except for leflunomide which requires ≥ 12 weeks) are permitted; * Oral prednisone ≤ 20 mg/day (or equivalent) is permitted; one increase or one decrease of ≤ 5 mg/day prednisone equivalent (not to exceed 20 mg/day) will be allowed within 30 days before randomization; Exclusion Criteria: * Any disorder (including psychiatric), condition or clinically significant disease (other than a diagnosis of DLE or SLE) that would, by its progressive nature and/or severity, interfere with the study evaluation, completion and/or procedures per the investigator's discretion; * History of malignancy; * Signs or symptoms or relevant history of a viral, bacterial, fungal, and parasitic infection, or recent history of repeated infections; * Subjects with evidence of past or active tuberculosis * Positive serology for HIV antibodies, hepatitis B surface antigen or hepatitis C antibodies (confirmed by PCR or RIBA) during the screening period; * Receipt of a live vaccine within 3 months of study randomization and during the study; * Prior use of the following agents: * Administration of an investigational biologic agent that primarily targets the immune system - * Rituximab, Lymphostat-B, or TACl-Ig within 9 months prior to randomization (or comparable B cell depleting or B cell inhibiting biologics); Rituximab (or other depleting CD20 targeted agents) treated patients must demonstrate a return of CD19+ B cells to \> 5/μL; * CTLA4-Ig within 3 months prior to randomization; * Other agents within 5 half-lives prior to randomization; * Administration of cyclosporine, tacrolimus, sirolimus, IV immunoglobulin, and/or plasmapheresis within 3 months of randomization; * Administration of thalidomide or lenalidomide within 3 months of randomization; * Administration of oral or IV cyclophosphamide (or any other alkylating agent) within 9 months of randomization;